Answers are grounded in this paper and cite their sources.
Phase II trial shows promising efficacy and safety of Toripalimab in muscle-invasive bladder cancer, suggesting a new treatment approach.
Toripalimab combined with GC chemotherapy demonstrates a good efficacy and safety, making it a promising therapeutic strategy for NAT of MIBC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: